Clinical Trials Browser

Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT05065736 2026-03-19

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Phase EARLY_PHASE1 Recruiting

4 enrolled

Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Neoplasms

NCT06645808 2025-12-29

VARTUTRACE

Phase EARLY_PHASE1 Recruiting

32 enrolled

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Osteosarcoma, Stomach Neoplasms

Clinical Trials

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

VARTUTRACE

REACT

Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors

PragMet

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

68Ga-NI-FAPI PET/CT: First-in-human Study

177Lu-JH04 in Patients with FAP-Positive Tumors

68Ga-ICAM-1pep PET/CT in Cancer Patients

Reboot-101

68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer

Neoantigen-T

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors